A new stem-cell technology with the potential to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) is now in development by the Israel Prize laureate responsible for the blockbuster multiple sclerosis (MS) drug Rebif.
Prof. Michel Revel’s company, Kadimastem, recently announced successful results ofa preclinical trial in which itslab-produced central nervous system support cells (astrocytes) demonstrated significant motor function and survivability improvement in a mouse model of ALS.
Revel based his approach on scientific evidence that ALS is characterized by malfunctioning astrocytes. Producing and then injecting healthy, functioning astrocytes into a patient’s nervous system seems to provide support for damaged motor neurons, slowing the progression of the disease, improving quality of life and even extending survival.Globally, 90 percent of ALS patients die of respiratory failure within three to five years after the onset of symptoms.
Kadimastem is now in touch with the US Food and Drug Administration as well as regulatory bodies in Israel and Europe, hoping to advance the technology to clinical trials.
More...
